Weight-Loss Medication has taken the world by story and helped many overweight people. But for some, significant weight loss also come with a loss of muscle mass and can lead to an increase Risk of osteoporosis.

New research now sugges that the drug bimagrumab may be removed Student Frederik Duch Bromer and Postdoc andreas Lodberg from the Department of Biomedicine at aarhus university, who are behind the study.

The work is Published in the Journal of Cachexia, Sarcopenia and Muscle,

“We are the first to study how the cinea drugs affect bones, and the results show Y Taking Weight-Loss Medication, “Say The authors.

Bimagramab was originally developed to treat muscle loss and dysfunction, but since then, it has become apparent that it also has also a fat-burning component to it. So, if approved, it would be part of a second-generation weight loss drug on the market.

“Therefore, it’s relevant to research how this particular patient group reacts to the drug,” Says lodberg. “An Estimated Two Billion People will be categorized as overweight by 2035, so it’s also important IR long-term impact on the body. “

Osteoporosis can prove costly for patients and socialy

Patients on Weight-Loss Medication often have a history of weight fluctuation, which can contribute to the development of osteoporosis. Brittle Bones Increase the Risk of Serious Fractures, and this is Costly for Both Patients and Society.

Therefore, The Research Results Could Be Good News for Patients on Weight-Loss Medication. And according to bromer, the study shows that bimagrumab not only counters the breakdown of bone and muscle tissue, it actually promotes the build-up of bot.

“Bimagramab Slightly Increases The Calcium Content in Bones and Promotes the Formation of New Bone in What We Call The Shell (Cortex) of the long bones. Al Head, which Is typically where many older people incur fractures, “Bromer Says.

According to bromer, the results also showed that bimagramab has no effect on the blood. Similar drugs have previously been shown to increase red blood cell production, increase the risk of blood clots.

The study is based on mice with bot osteoporosis and reduced muscle mass, and the drug is now being tested in Several Phase 2 Clinical Trials. Lodberg Emphasizes that more research is needed: “Our Study Shows that Bimagrumab has a positive effect in many ares This further to get a clearer picture of The implications of using the drug for patients. “

Lodberg and bromer hope to be able with further research to investigate both the positive results and possible side effects.